BRIEF-Lilly and Astrazeneca receive FDA fast track designation for AZD3293
August 22, 2016 at 06:18 AM EDT
* Lilly and Astrazeneca receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer's disease
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.